Cancer: Catalytic

Nanomedicine
Tessy López
Universidad Autónoma Metropolitana
National Institute of Neurology and
Neurosurgery
tessy3@prodigy.net.mx
 What is cancer?

Is a term used for diseases in which abnormal cells divide

without control and are able to invade other tissues. Cancer
cells can spread to other parts of the body through the blood
and lymphatic systems (metastasize).
 Classifica
tion describes
This classification
the type of tissue in which the
cancer cells begin to develop.

• Adenocarcinoma - originates in
tissue
• Glioma – glial tissue
• Carcinoma– epithelial tissue
• Leukemia– blood cells
• Lymphoma– lymphatic tissue
• Myeloma– bone marrow
• Sarcoma– connective tissue
Most cancers are named for
the organ or type of cell in
which they begin.
Glioblastoma Multiforme
(GBM) are 35% brain cancer,
according to the OMS
statistics. Those are the
primary and more frequent
tumors of the Central
Nervous System (CNS).
 NANOMEDICINE AND
CANCER
Nanotechnology has
been applied in all
therapeutic areas of
medicine.
The most extensive
investigations are in
cancer.
Nanoparticles can
deliver chemotherapy
drugs directly to tumor
cells and then give off a
signal after the cells are
destroyed. Drugs
delivered this way are
• The treatment of Central Nervous
System (CNS) is difficult due to the
Blood Brain Barrier (BBB) cross.

• Only low molecular weight

molecules, liposolubles, and any
peptidic compounds cross the BBB.

MECHANISM

Passive diffusion or specific

Local application or direct tumor injection of
cytotoxic drugs has been proposed as a
technique to use 100% .
Systemic exposure and non-target organ
toxicity is minimized
PRODUCT IN THE MARQUET
Gliadel: Drug delivery system
of carmustine in CNS to GBM

Only release the

chemotherapy
during 10 days.
 We have an alternative drug delivery
System. This deliver during six months
the
Following drugs: Carmustine and
Release from TiO Release from SiO
Methotrexate
2 2

Tumor with C6
cancer cells
Sol-gel device with drug
Catalytic Nanomedicine
is a new way to treat
We made a catalytic process
in the nucleotides of the
BIO-CATALYST UAM-INNN
1. Cis Pt/SBA-15
2. Pt(acac)2/SiO2
3. Pt(acac)2/TiO2
4. H2PtCl6/SiO2
5. H2PtCl6/TiO2
6. Temozolomida/TiO2
7. (NH2)4Cl2Pt/ SiO2
8. Doxorubicina/SiO2
9. Metotrexato/SiO2
10.Cis-diamindicloro-Platino (II)
B
11.Cis-diamindicloro-Platino (II)
A
CHARACTERIZA
TION
Particle size of the
Support = 30 nm
Particle size of the
Platinum = 3-5 nm

Pt/SiO
2

640
m2/g
Brönsted and
Lewis acid sites
C6 cellular model was Pt/TiO
used to form 2

a tumor of 5 cm of
diameter.

n = 70
Control Platinum complex

Titania Titania-Platinum
 60
Tumoral weight reduction
50 24.6%

43.4%
Tumoral weigth (gr)

40
55.7%
96%

30
*

20

10

0
CONTROL Pt TiO2 TiO2-Pt

*p=0.03 when compared with control

Average tumor size of C6 glioma in rats after treatment

Particl
es
• A significant growth inhibition
was observed in animal treated
with Platinum-titania .
• The existence of stronger
electron-acceptor centers (Ti4+
and Ti3+ions) that can coordinate
with basic molecules placed at
DNA and promoted the apoptosis
mechanism.
Degradation of DNA studies with
our different
Nanoparticles: control release
delivery and

t=72
horas
1 2 3 4 5 6 7 8

t=0 t= 3 t=5 t=10

Thank you…